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Abstract
Human epidermal growth factor receptor 2 (HER2) is one of the most important prognostic and predictive factors for breast
cancer patients. Recently, serum HER2 ECD level of patients detected by enzyme-linked immunoabsorbent assay (ELISA) has
been shown to predict tumor HER2 status and reveal its association with tumor progression, recurrence and poor prognosis.
In this study, we established a new method, dot blot assay, to measure the serum HER2 level in breast cancer patients and
further to evaluate the clinical value for monitoring breast cancer progression. We found that the serum HER2 level
measured by dot blot assay was significantly correlated with tissue HER2 status in breast cancer patients (P=0.001), and also
significantly correlated with HER2 level measured by ELISA (P=1.06610
211). Compared with ELISA method, the specificity
and sensitivity of dot blot assay were 95.3% and 65.0%, respectively. The serum HER2 levels of patients with grade III or ER-
negative were higher than those with grade I–II (P=0.004) and ER-positive (P=0.033), respectively. Therefore, the novel dot
blot method to detect serum HER2 level is a valid and inexpensive assay with potential application in monitoring breast
cancer progression in clinical situations.
Citation: Tan L-D, Xu Y-Y, Yu     Y, Li X-Q, Chen Y, et al. (2011) Serum HER2 Level Measured by Dot Blot: A Valid and Inexpensive Assay for Monitoring Breast Cancer
Progression. PLoS ONE 6(4): e18764. doi:10.1371/journal.pone.0018764
Editor: Irina Lebedeva, Enzo Life Biosciences, United States of America
Received September 20, 2010; Accepted March 17, 2011; Published April 13, 2011
Copyright: 2011 Tan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Natural Science Foundation of China (No. 30872518), the Major Program of Applied Basic Research Projects of
Tianjin (No. 09JCZDJC19800) and the Program for Changjiang Scholars and Innovative Research Team in University by the Ministry of Education (No. URT0743).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ymfeng@tijmu.edu.cn
. These authors contributed equally to this work.
Introduction
Breast cancer is one of most common malignant tumors with
the highest incidence and the second highest mortality among all
malignant tumors in females [1]. Molecular techniques have
greatly promoted the detection and prediction of prognosis and
treatment response of breast cancer. An important instance is the
detection of overexpression of human epidermal growth factor
receptor 2 (HER2), which is present in 10–25% of breast cancer
[2]. HER2 is a transmembrane tyrosine kinase receptor belonging
to a family of epidermal growth factor receptors structurally
related to the epidermal growth factor receptor (EGFR), and is
encoded by ERBB2/HER2 oncogene located on chromosome
17q21 [3,4]. Deregulated expression of HER2 has been implicated
in the development of numerous types of human cancers [5].
Amplification of ERBB2 gene or overexpression of HER2 protein
is one of the most important prognostic factors in breast cancer
patients [3,6,7] Therefore, HER2 has been a target for specific
breast cancer treatment with the monoclonal antibody trastuzu-
mab (HerceptinH) which was approved in 1998 by the United
States Food and Drug Administration (FDA). The benefit of this
particular therapy has been sufficiently confirmed in metastatic
breast carcinomas [8]. In addition to trastuzumab, other
therapeutic strategies have been developed recently to target the
HER2 protein, such as the tyrosine kinase inhibitor lapatinib,
which appears to have efficacy after failure of trastuzumab therapy
[9].
HER2 status of breast cancer is routinely assessed by either
immunohistochemical (IHC) analysis of HER2 protein or by
fluorescent in situ hybridization (FISH) analysis of ERBB2 gene
copy number in primary tumor tissues. Recently it was shown that
HER2 extracellular domain (ECD) can be shed into the
circulation by proteolytic cleavage from the full-length HER2
receptor, and is detected in the serum of women with benign
breast disease, primary and metastatic breast cancer [10].
Overwhelming evidence demonstrated that serum HER2 level
has the potential value to predict tumor HER2 status as detected
by IHC [11,12] and is associated with tumor progression,
recurrence and poor prognosis [13,14,15]. In fact, assay for serum
HER2 ECD level has been approved by the FDA for the follow-up
and monitoring of patients undergoing various treatments for
metastatic breast cancer [11,16]. Up to now, the ‘‘soluble’’
receptor is mainly analyzed with the enzyme-linked immunoab-
sorbent assay (ELISA) method [15]. In the present study, we
established a new method, dot blot, to measure the serum HER2
level and further evaluated their clinical value for predicting tumor
HER2 status and tumor progression.
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HER2 expression in primary breast cancer tissues
The western blot showed that the HER2 antibody is very
specific, detecting the p185 HER2 protein (Fig. 1A). Thus this
antibody is suitable to be used in IHC staining to detect tissue
HER2 status and dot blot assay to detect the serum HER2 level.
Representative HER2 immunostaining of primary breast cancer
tissues is shown in Fig. 1B and the localization of HER2 was
restricted to the cell membrane. Among 126 cases, 64.3% (81/
126) patients were HER2 negative (0), 13.5% (17/126) patients
were weakly positive (1+), 15.1% (19/126) were moderately
positive (2+), and 7.1% (9/126) were strongly positive (3+).
Serum HER2 levels was detected by dot blot
By dot blot assay, the concentration of serum HER2 in 133
breast cancer patients were determined to range from 0.7 ng/ml
to 133.1 ng/ml, median 20.5 ng/ml (Fig. 2). All samples were
divided into four groups according to the baseline serum HER2
levels: negative HER2 (0; less than 19 ng/ml), weakly positive
HER2 (1+; from 19 to 32 ng/ml), moderately positive HER2 (2+;
from 32 to 66 ng/ml), and strongly positive HER2 (3+; more than
66 ng/ml). Notably, the serum HER2 levels detected by dot blot
assay and tissue HER2 status examined by IHC were positively
correlated in 126 primary breast cancer patients (Spearman’s
rho=0.301, P=0.001; Table 1, Fig. 3A).
Correlation between ELISA and dot blot in serum HER2
detection
A total of 63 patients showed correlation between serum HER2
levels detected by dot blot and tissue HER2 status detected by
IHC. The serum HER2 levels of these 63 patients were measured
using ELISA and found to be in the range of 2.3 to 112.5 ng/ml.
Among the patients, 18 (28.6%) were judged as HER2 (0; less than
Figure 1. HER2 expression in primary breast cancer tissues. (A), Western blot analysis of HER2 in representative primary breast cancer tissues
and MDA-MB-435/ERBB2 cell line (top panel). b-actin served as loading control (bottom panel). (B), Representative IHC staining for HER2 in breast
cancer tissues classified as negative (0; a), weak positive (1+; b), moderate positive (2+; c), and strong positive (3+; d) for HER2 expression.
doi:10.1371/journal.pone.0018764.g001
Figure 2. The serum HER2 level detected by dot blot assay. (A), The digitized image of the dot blot assay of the soluble serum HER2. Samples
a1 to a7 are standards, sample a8 is the blank control, rows c and e are the tested samples, and rows b, d, and f are duplicates of a, c, e, respectively.
(B), The standard curve of soluble HER2 levels.
doi:10.1371/journal.pone.0018764.g002
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(22.2%) were HER2 (2+; from 28 to 59 ng/ml), and 6 (9.5%) were
HER2 (3+; more than 59 ng/ml). Most significantly, the serum
HER2 levels detected by ELISA and dot blot assay were positively
correlated (Spearman’s rho=0.731, P=1.06610
211; Table 1,
Fig. 3B). The HER2 0/1+ was grouped into the low expression
group, which should not receive trastuzumab treatment. Com-
pared with the ELISA, the specificity (HER2; 0/1+) and sensitivity
(HER2; 2+/3+) of the dot blot assay were 95.3% (41/43) and
65.0% (13/20), respectively.
Relationship between baseline serum HER2 levels and
clinicopathological variables
By dot blot assay, the serum HER2 levels of patients with grade
III or ER-negative were higher than those with grade I–II
(P=0.004) or ER-positive (P=0.033), respectively. No significant
relationships were found between HER2 levels and other
clinicopathological variables, such as age, menopausal status,
clinical stage, lymph nodes involvement or PR status. Moreover,
we compared serum HER2 level in invasive and non-invasive
ductal carcinoma and found that serum HER2 levels were higher
in patients with invasive ductal carcinoma than patients with
ductal carcinoma in situ, but no significant difference was revealed
between these two groups since there were only 8 cases of ductal
carcinoma in situ (Table 2).
Discussion
Amplification of ERBB2 oncogene and/or overexpression of
HER2 protein in breast cancer have been linked to poor prognosis
and a differential response to a variety of systemic treatments [11],
therefore, HER2 status plays an important role in the prognosis
and prediction for breast cancer patients. With the availability of
the monoclonal antibody trastuzumab as an effective therapy for
metastatic breast cancer, there is an increased need to evaluate
HER2 status to identify those patients who might benefit from this
treatment and to monitor disease progression. Clinically, HER2
status is most often determined in tissues from primary or
metastatic breast cancer by IHC assay that examines the protein
expression or by FISH assay that determines gene amplification.
Results of these tests are generally in agreement, although
discrepancies are possible due to inherent variability in proce-
dures, lack of standardization and subjective interpretation [17].
Interestingly, several lines of recent evidence suggest that HER2
serum level might provide a novel and useful tool for management
of patients with breast cancer, as it might predict prognosis,
treatment selection and clinical response. Isola et al [18]
Table 1. Correlations among HER2 status detected by IHC, ELISA and Dot blot assay.
HER2 status Cases
Median serum
HER2 levels by
dot blot (ng/ml) Rank sum tests Serum HER2 levels by dot blot
Spearman rank
correlation
Z/x
2 P 0–1+ 2+ 3+ rP
IHC for tissue 126
0–1+ 98 18.0 7.291 0.026 72 (73.4) 13 (13.3) 13 (13.3) 0.301 0.001
2+ 19 42.1 8 (42.1) 9 (47.4) 2 (10.5)
3+ 9 90.9 3 (33.3) 0 (0.0) 6 (66.7)
ELISA for serum
0–1+ 43 15.9 29.058 4.90610
212 41 (95.3) 2 (4.7) 0 (0.0) 0.731 1.06610
211
2+ 14 30.5 7 (50.0) 7 (50.0) 0 (0.0)
3+ 6 93.7 0 (0.0) 0 (0.0) 6 (100.0)
doi:10.1371/journal.pone.0018764.t001
Figure 3. Correlations among HER2 status detected by IHC, ELISA and Dot blot assay. (A), Correlation between tissue HER2 status and
serum HER2 levels. The horizontal dash lines indicated the median values in each group. (B), Correlation between dot blot assay and ELISA for the
detection of serum HER2 levels. The horizontal dash lines indicate the median values in each group.
doi:10.1371/journal.pone.0018764.g003
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progression of patients with HER2-positive breast carcinoma.
Kandl et al [19] reported a correlation between elevated serum
HER2 and poor prognosis of advanced breast carcinoma. In
addition, both Willsher et al [20] and Rocca et al [21] showed the
prognostic importance of serum HER2 in early breast carcinoma
patients. Molina et al [22] demonstrated that abnormal presurgical
serum HER2 was related to the poor prognosis of node-positive
and node-negative breast carcinoma. Furthermore, Ludovini et al
[23] showed a shorter disease-free survival in patients with
elevated serum HER2 ECD levels. Most notably, assay for serum
HER2 ECD has been approved by the FDA for the follow-up and
monitoring of patients undergoing treatment for metastatic breast
cancer on various therapies [11,16,24]. Therefore, the reassess-
ment of HER2 status based on HER2 serum level during disease
progression might help optimize treatment strategy by identifying
patients who could profit from trastuzumab or other HER2
targeted therapy [25,26] There is good evidence showing that
shedding of HER2 ECD only occurs in those patients whose
tumors show HER2 amplification/overexpression [27]. In our
present study, we established a novel method, dot blot, for the
detection of serum HER2 levels, and found statistically significant
correlation between the tissue HER2 status as detected by IHC
and the serum HER2 level as detected by dot blot assay.
Moreover, serum HER2 level determined by dot blot assay
showed a significant correlation with that determined by ELISA,
the most widely used method to detect the serum HER2 ECD
level. Strikingly, the results of dot blot assay were more consistent
with IHC analysis. Thus our results suggested that serum HER2
levels determined by dot blot assay might aid the assessment of
Table 2. Association between serum HER2 levels and clinicopathological variables (N=133).
Variables Cases Serum HER2 levels by dot blot Chi-squae test
0–1+(%) 2+ (%) 3+ (%) x
2 P
Age (years)
#45 33 20 (60.6) 10 (30.3) 3 (9.1) 6.394 0.172
45–55 47 31 (66.0) 7 (14.9) 9 (19.1)
.55 53 36 (67.9) 6 (11.3) 11 (20.8)
Menopausal status
Premenopausal 60 40 (66.7) 14 (23.3) 6 (10.0) 5.695 0.058
Postmenopausal 73 47 (64.4) 9 (12.3) 17 (23.3)
Pathology diagnosis
Ductal carcinoma in situ 8 6 (75.0) 0 (0.0) 2 (25.0) 0.884 0.390
Invasive ductal carcinoma 125 81 (64.8) 23 (18.4) 21 (16.8)
Tumor size (cm)
#2 44 31 (70.5) 9 (20.5) 4 (9.0) 3.042 0.218
.2 71 48 (67.6) 9 (12.7) 14 (19.7)
Missing 18
Clinical stage
I 40 30 (75.0) 4 (10.0) 6 (15.0) 1.497 0.473
II+III 84 55 (65.5) 15 (17.9) 14 (16.6)
Missing 9
Histological grade
I+II 86 62 (72.1) 15 (17.4) 9 (10.5) 10.906 0.004
III 14 5 (35.7) 3 (21.4) 6 (42.9)
Missing 33
Lymph node status
Negative 75 51 (68.0) 9 (12.0) 15 (20.0) 5.510 0.064
Positive 48 30 (62.5) 13 (27.1) 5 (10.4)
Missing 10
ER status
Positive 71 49 (69.0) 15 (21.1) 7 (9.9) 6.844 0.033
Negative 53 33 (62.3) 6 (11.3) 14 (26.4)
Missing 9
PR status
Positive 40 30 (75.0) 7 (17.5) 3 (7.5) 3.818 0.148
Negative 84 52 (61.9) 14 (16.7) 18 (21.4)
Missing 9
doi:10.1371/journal.pone.0018764.t002
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investigator’s subjective view.
Based on a systematic review of the literature, Carney et al [28]
reported that the prevalence of elevated serum HER2 ECD levels
was approximately 18% (range 0–38%) in primary breast cancer
(2,623 women in 25 studies) but increased to 43% (range 23–80%) in
metastatic breast cancer (4,622 women in 45 studies). However, our
results indicated that the elevated serum HER2 levels were 25.0%
(2+/3+) in non-invasive ductal carcinoma and 35.2% (2+/3+)i n
invasive ductal carcinoma. The discrepancy may be caused by the
specificity of HER2 antibody, small sample size, different standards
for positive, different histological types of breast cancer and the ethnic
differences. Consistent with the report by Ludovini et al [23], the
elevated serum HER2 level was observed in patients with high
histological grade and ER negativity, suggesting that these patients
had a high risk of metastasis. Taken together, in this study, serum
HER2 level determined by dot blot can serve as a biomarker for the
prediction of aggressive tumor and progression of breast cancer.
Compared with ELISA, which requires the inclusion of pre-
coating antibody, dot blot assay greatly reduces the amount of
antibody and the sample. In this study, we arrayed serum samples
on solid phase membrane to concentrate protein. For the 48-point
density, only 2 ml serum of each sample is needed. In addition,
only 5 mg antibody per 96-well is required, much less than 20 mg
antibody per 96-well required for ELISA. Therefore, the cost of
dot blot is much cheaper than ELISA. Based on this method,
increasing the dot density to make a high-density array will
significantly reduce the amount of serum samples and the antibody
required for each sample. This method is especially suitable for
testing a large number of samples. Further optimization of this dot
blot assay is necessary in terms of the sample print system,
detection system and analysis system.
Because of the difficulties associated with standardization of
preanalytical and analytical as well as postanalytical factors, the
use of experimental controls is essential to guarantee reliable
results. Each array should include negative (normal serum) and
positive (known concentration of serum HER2) controls. The
mean ( X X) and standard deviation (s) of quality controls are
calculated by multiple batches. If the concentration of quality
controls is within  X X62s, the assay is considered reliable results.
In conclusion, to our knowledge, this is the first report of the
development and evaluation of dot blot assay for the detection of
serum HER2 level in breast cancer patients. Although we
demonstrate that this assay showed significant correlation with
ELISA as well as IHC, due to the limited size of patients, our
results need to be confirmed in large prospective trials before the
simple and inexpensive dot blot assay can be routinely used in the
clinical for monitoring breast cancer progression.
Materials and Methods
Patients and specimens
A total of 133 breast cancer patients (aged 26–84 years, mean
age 53 years) were recruited for this study from July to September
2008 in Tianjin Medical University Cancer Institute and Hospital
(TMUCIH; Tianjin, China). Among them, 116 (87.2%) patients
underwent unilateral radical mastectomy and dissection of axillary
lymph nodes, 10 (7.5%) patients underwent local tumorectomy or
breast-conserving surgery, and 7 (5.3%) patients did not undergo
surgery. All diagnoses were confirmed based on pathological
examination and 2003 WHO Classification of Tumors of the
Breast, and 125 (94.0%) cases were invasive ductal carcinoma and
8 (6.0%) were ductal carcinoma in situ. Detailed clinicopatholog-
ical information including menopausal status, clinical stage, tumor
size, histological grade, lymph node involvement, as well as
estrogen receptor (ER) and progesterone receptor (PR) status is
presented in Table 3. ER and PR status were determined by
immunohistochemical staining and defined as positive if more than
15% of tumor cells showed positive nuclear staining.
From each individual, 2 ml fasting peripheral blood was
collected into BD Vacutainer tubes without anticoagulant (BD
Biosciences, Franklin Lakes, NJ, USA) before surgery. The blood
was centrifuged at 3,000 g for 10 min at room temperature, and
serum was then stocked in 0.5 ml aliquots and stored at 280uC.
The study protocol was approved by the Institutional Review
Board of Tianjin Medical University Cancer Institute and
Hospital (TMUCIH; Tianjin, China) and written consent was
obtained from all participants.
Table 3. Clinicopathological characteristics of breast cancer
patients (N=133).
Characteristics Cases (%)
Menopausal status
Premenopausal 60 (45.1)
Postmenopausal 73 (54.9)
Pathology diagnosis
Invasive ductal carcinoma 125 (94.0)
ductal carcinoma in situ 8 (6.0)
Clinical Stage
I 40 (30.1)
II 80 (60.1)
III 4 (3.0)
Missing 9 (6.8)
Tumor size (cm)
#2 44 (33.1)
2–5 68 (51.1)
.5 3 (2.3)
Missing 18 (13.5)
Lymph nodes involvement
Negative 75 (56.4)
Positive 48 (36.1)
Missing 10 (7.5)
Histology grade
I 9 (6.8)
II 77 (57.9)
III 14 (10.5)
Missing 33 (24.8)
ER status
Positive 71 (53.4)
Negative 53 (39.8)
Missing 9 (6.8)
PR status
Positive 40 (30.0)
Negative 84 (63.2)
Missing 9 (6.8)
Note: ‘‘Missing’’ indicates the number (%) of cases for which the corresponding
information was not available.
doi:10.1371/journal.pone.0018764.t003
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MDA-MB-435 cell line was obtained from the American Type
Culture Collection (ATCC). ERBB2-transfected MDA-MB-435
(435/ERBB2)c e l ll i n ew a sag i f tf r o mD r .M i e n - C h i eH u n ga n d
Dr. Wei Zhang (University of Texas M. D. Anderson Cancer Center,
Houston, TX). The cells were cultured in DMEM-F12 Medium
(GIBCO,Carlsbad, CA,USA) supplemented with 10% newborncalf
serum (GIBCO), 100 U/ml penicillin and 100 mg/ml streptomycin.
The cells grown to 80% confluence were used for experiments.
Western blot assay
Cancertissues orcultured cellswere lysed with proteinlysis buffer
containing 20 mM Tris-HCl pH 7.4, 5 mM EDTA, 1% Triton-X
100, 150 mM NaCl, 1% DTT, and 1% protease inhibitor cocktail
(Sigma, St. Louis, MO, USA). The proteins in the lysate were
separated by SDS-PAGE and transferred to polyvinyldifluoride
membranes (Pierce, Rockford, IL, USA). The membranes were
blocked in 5% skimmed milk in TBST (10 mM Tris, 150 mM
NaCl, 0.05% Tween 20, pH 8.3) for 1 hour at room temperature,
then incubated with a 1:1000 dilution of rabbit polyclonal HER2
antibody (A0485, DAKO, Denmark) in 1% skimmed milk in TBST
at 4uC overnight. The following day, the membranes were washed
in TBST and then incubated with HRP-conjugated goat anti-rabbit
(GE Healthcare, Piscataway, NJ, USA) at a dilution of 1:2500 for
45 min at room temperature. The membranes were then washed in
TBST and immunoreactive protein bands were visualized by
enhanced chemiluminescence (ECL) reagents (GE Healthcare).
Immunohistochemistry
Breast cancer tissue was obtained by either breast core-needle
biopsy or surgery. Immunohistochemistry (IHC) staining of
specimens was carried out on formalin-fixed paraffin-embedded
tissues using the polyclonal rabbit HER2 antibody (A0485;
DAKO) at a dilution of 1:400, and a peroxidase-conjugated
detection system (DAKO). Development was performed with
diaminobenzidine, using hematoxylin counterstaining. HER2
IHC staining was scored as (0), weak positive (1+), moderate
positive (2+) and strong positive (3+) based on the percentage of
cells stained as positive and staining intensity following the
standard of DAKO Hercept Test
TM (Fig. 1).
Dot blot assay
Two ml serum was diluted 100-fold with TBS buffer and then
spotted onto nitrocellulose membrane with Bio-Dot Microfiltra-
tion Apparatus (Bio-Red, Hercules, CA, USA). All samples were
deposited in random order on the 48-spot membrane. In addition,
HER2 from MDA-MB-435/ERBB2 cell lysate with a known
concentration was diluted as 1:5
2, 1:5
3, 1:5
4, 1:5
5, 1:5
6, and 1:5
7
(0.2, 1, 5, 25, 125 and 675 ng/ml) to be used as extrapolation
standards. The membranes were probed with the same antibody
as for western blot. The light intensity of a single spot on the
membrane was detected using a ChemiDocXRS imaging system
(Bio-Rad). Based on the light intensities of HER2 protein
concentration standards, the concentration of serum HER2 in
each spot was calculated. All samples were performed in duplicates
(Fig. 2).
Enzyme-linked immunosorbent assay
In cases where serum HER2 level, detected by dot blot, was
consistent with tissue HER2 status examined by IHC, the HER2
level was also measured using a sandwich ELISA Kit (Bender
MedSystem, Vienna, Austria) following manufacturer’s instruc-
tions. 100 ml of diluted serum samples, controls, and standards
were micropipetted in the designated wells, and then 50 mlo f
HRP-Conjugate were added into each well and incubated at room
temperature for 2 h. After washing, the substrate tetramethylben-
zidine (TMB) was added into the wells and the reaction was
terminated by addition of Stop Solution, and absorbance was
measured at 450 nm. All experiments were performed in a blinded
manner and in duplicates, and the HER2 concentration was
calculated using their average optical densities based on standard
curves.
Statistical analyses
All statistical analyses were performed with Statistical Package
for the Social Sciences (SPSS, version 13.0). Spearman rank
correlation and rank sum test was used to analyze the correlations
between HER2 levels detected by IHC, dot blot or ELISA. Chi-
square (x
2) test or Fisher’s exact test, and rank sum test was used to
compare the serum HER2 level among cancer patients with
various clinicopathological parameters. P-values of less than 0.05
were considered as statistically significant.
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